Compounds > wck 771
Page last updated: 2024-11-11

wck 771

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

WCK 771: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9850037
CHEMBL ID190465
SCHEMBL ID5213674
MeSH IDM0473216

Synonyms (14)

Synonym
CHEMBL190465
u2rv55f5o0 ,
306748-89-0
wck 771
l-arginine, mono((5s)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1h,5h-benzo(ij)quinolizine-2-carboxylate)
levonadifloxacin arginine salt
unii-u2rv55f5o0
l-arginine, (5s)-9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1h,5h-benzo(ij)quinolizine-2-carboxylate (1:1)
levonadifloxacin arginine
SCHEMBL5213674
DTXSID60184714
l-arginine compound with (s)-9-fluoro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-6,7-dihydro-1h,5h-pyrido[3,2,1-ij]quinoline-2-carboxylic acid (1:1)
(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;(12s)-7-fluoro-8-(4-hydroxypiperidin-1-yl)-12-methyl-4-oxo-1-azatricyclo[7.3.1.05,13]trideca-2,5,7,9(13)-tetraene-3-carboxylic acid
Q27290601

Research Excerpts

Overview

WCK 771 is a broad-spectrum fluoroquinolone with enhanced activity against quinolone-resistant staphylococci. It has recently completed a phase III trial in India.

ExcerptReferenceRelevance
"WCK 771 is an l-arginine salt of levonadifloxacin (LND) being developed in intravenous dosage form and has recently completed a phase III trial in India. "( Identification of metabolites of novel Anti-MRSA fluoroquinolone WCK 771 in mouse, rat, rabbit, dog, monkey and human urine using liquid chromatography tandem mass spectrometry.
Ahirrao, VK; Chavan, RP; Deshpande, PK; Patel, AM; Patel, MV; Patil, KR; Rane, VP; Yeole, RD, 2019)		2.19
"WCK 771 is a broad-spectrum fluoroquinolone with enhanced activity against quinolone-resistant staphylococci. "( The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase
Bhagwat, SS; Gupte, SV; Khorakiwala, HF; Mundkur, LA; Patel, MV, 2006)		2.02

Dosage Studied

ExcerptRelevanceReference
"WCK 771 is an l-arginine salt of levonadifloxacin (LND) being developed in intravenous dosage form and has recently completed a phase III trial in India."( Identification of metabolites of novel Anti-MRSA fluoroquinolone WCK 771 in mouse, rat, rabbit, dog, monkey and human urine using liquid chromatography tandem mass spectrometry.
Ahirrao, VK; Chavan, RP; Deshpande, PK; Patel, AM; Patel, MV; Patil, KR; Rane, VP; Yeole, RD, 2019)		2.19
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (22)

Assay IDTitleYearJournalArticle
AID246899Protection of mice infected with MRSA-32 cell suspension after oral administration of compound2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID544291Antibacterial activity against Staphylococcus aureus after 24 hrs by CLSI method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID544303Antibacterial activity against vancomycin-resistant Staphylococcus aureus VRS3 harboring GyrA S84L and GrlA S80F, E84K mutant after 24 hrs by CLSI method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID544308AUC in human at 800 mg, iv qd after 24 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID544294Antibacterial activity against hospital acquired methicillin-resistant Staphylococcus aureus after 24 hrs by CLSI method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID544295Antibacterial activity against vancomycin-intermediate Staphylococcus aureus after 24 hrs by CLSI method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID544310Ratio of AUC in human to MIC for Staphylococcus aureus after 24 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID544292Antibacterial activity against methicillin-susceptible Staphylococcus aureus after 24 hrs by CLSI method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID544309Fraction unbound in human at 800 mg, iv qd after 24 hrs2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID544293Antibacterial activity against community acquired methicillin-resistant Staphylococcus aureus after 24 hrs by CLSI method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID544299Antibacterial activity against vancomycin-intermediate Staphylococcus aureus Mu3 harboring GyrA S84L and GrlA S80F mutant after 24 hrs by CLSI method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID544302Antibacterial activity against vancomycin-resistant Staphylococcus aureus VRS2 harboring GyrA S84L and GrlA S80F mutant after 24 hrs by CLSI method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID544296Antibacterial activity against quinolone-resistant Staphylococcus aureus after 24 hrs by CLSI method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID544304Antibacterial activity against vancomycin-resistant Staphylococcus aureus VRS5 harboring GyrA S84L, E88K and GrlA S80F, E84G mutant after 24 hrs by CLSI method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID544301Antibacterial activity against vancomycin-resistant Staphylococcus aureus VRS1 harboring GyrA S84L and GrlA S80F mutant after 24 hrs by CLSI method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID544297Antibacterial activity against vancomycin-susceptible methicillin-resistant Staphylococcus aureus 32 harboring GyrA S84L and GrlA S80Y mutant after 24 hrs by CLSI method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID544305Antibacterial activity against vancomycin-resistant Staphylococcus aureus VRS6 harboring GyrA S84L and GrlA S80F, E84G mutant after 24 hrs by CLSI method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID544306Antibacterial activity against vancomycin-resistant Staphylococcus aureus VRS7 harboring GyrA S84L and GrlA S80F mutant after 24 hrs by CLSI method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID544300Antibacterial activity against vancomycin-intermediate Staphylococcus aureus Mu50 harboring GyrA S84L and GrlA S80F mutant after 24 hrs by CLSI method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID544307Antibacterial activity against vancomycin-resistant Staphylococcus aureus VRS4 harboring GyrA S84L and GrlA S80F, E84K mutant after 24 hrs by CLSI method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
AID244913Minimum inhibitory concentration against methicillin susceptible Staphylococcus aureus2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID544298Antibacterial activity against vancomycin-susceptible methicillin-resistant Staphylococcus aureus 34 harboring GyrA S84L and GrlA S80F mutant after 24 hrs by CLSI method2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's11 (73.33)29.6817
2010's4 (26.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.56 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.33 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (6.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (93.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
ciprofloxacin
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.		2.0210aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
nadifloxacin
nadifloxacin: (R)-isomer does not induce chromosomal aberrations, unlike (S)-isomer; structure given in first source		8.8130heteroarylpiperidine;
hydroxypiperidine;
pyridoquinoline;
quinolone antibiotic		antibacterial drug
norfloxacin
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.. norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.		2.0210fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug;
DNA synthesis inhibitor;
environmental contaminant;
xenobiotic
gatifloxacin
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.. gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.		2.0210N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antiinfective agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
carbostyril
Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.		2.9740monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite
methicillin
Methicillin: One of the PENICILLINS which is resistant to PENICILLINASE but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection.. methicillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 2,6-dimethoxybenzoyl group.		7.2110penicillin allergen;
penicillin		antibacterial drug
vancomycin
Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.		2.4420glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
pefloxacin
Pefloxacin: A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.. pefloxacin : A quinolone that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6 and 7 by ethyl, carboxy, fluorine, and 4-methylpiperazin-1-yl groups, respectively.		2.0210fluoroquinolone antibiotic;
monocarboxylic acid;
N-alkylpiperazine;
N-arylpiperazine;
quinolone antibiotic;
quinolone		antibacterial drug;
antiinfective agent;
DNA synthesis inhibitor
sparfloxacin
[no description available]		2.0210fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone
trovafloxacin
trovafloxacin: a trifluoronaphthyridone derivative of 7-(3-azabicyclo(3.1.0)hexyl)naphthyridone; has antineoplastic activity. trovafloxacin : A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 6-amino-3-azabicyclo[3.1.0]hex-3-yl substituents at positions 1, 6 and 7 respectively. A broad-spectrum antibiotic that was withdrawn from the market due to risk of liver failure.		2.0210
levofloxacin
Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.		2.02109-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;
fluoroquinolone antibiotic;
quinolone antibiotic		antibacterial drug;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor
moxifloxacin
Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.		2.4420aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug
linezolid
[no description available]		2.0210acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
betadex
beta-Cyclodextrins: Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds.		2.0310cyclodextrin
(S)-nadifloxacin
levonadifloxacin: broad-spectrum anti-MRSA benzoquinolizine quinolone agent		2.0210nadifloxacin
ly-146032
[no description available]		2.0210heterodetic cyclic peptide;
lipopeptide antibiotic;
lipopeptide;
macrocycle;
macrolide		antibacterial drug;
bacterial metabolite;
calcium-dependent antibiotics
piperidines
Piperidines: A family of hexahydropyridines.		2.0210
ConditionIndicatedRelationship StrengthStudiesTrials
Infections, Staphylococcal
[description not available]		03.1450
Staphylococcal Infections
Infections with bacteria of the genus STAPHYLOCOCCUS.		03.1450
Health Care Associated Infection
[description not available]		02.0510
Cross Infection
Any infection which a patient contracts in a health-care institution.		02.0510
Infections, Chlamydia
[description not available]		02.2110
Chlamydia Infections
Infections with bacteria of the genus CHLAMYDIA.		02.2110
Bacterial Disease
[description not available]		02.0210
Bacterial Infections
Infections by bacteria, general or unspecified.		02.0210
Blood Poisoning
[description not available]		02.0210
Phlegmon
[description not available]		02.0210
Cellulitis
An acute, diffuse, and suppurative inflammation of loose connective tissue, particularly the deep subcutaneous tissues, and sometimes muscle, which is most commonly seen as a result of infection of a wound, ulcer, or other skin lesions.		02.0210
Sepsis
Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.		02.0210
Pneumonia, Pneumococcal
A febrile disease caused by STREPTOCOCCUS PNEUMONIAE.		02.0210
Bacteremia
The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.		02.0210
Sore Throat
[description not available]		02.0210
Infections, Pneumococcal
[description not available]		02.0210
Injuries
Used with anatomic headings, animals, and sports for wounds and injuries. Excludes cell damage, for which pathology is used.		02.0210
Group A Strep Infection
[description not available]		02.0210
Pharyngitis
Inflammation of the throat (PHARYNX).		02.0210
Pneumococcal Infections
Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE.		02.0210
Streptococcal Infections
Infections with bacteria of the genus STREPTOCOCCUS.		02.0210
Tonsillitis
Inflammation of the tonsils, especially the PALATINE TONSILS but the ADENOIDS (pharyngeal tonsils) and lingual tonsils may also be involved. Tonsillitis usually is caused by bacterial infection. Tonsillitis may be acute, chronic, or recurrent.		02.0210
Wounds and Injuries
Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.		02.0210
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.4420
Acne
[description not available]		02.9410
Infections, Staphylococcal Skin
[description not available]		02.9410
Acne Vulgaris
A chronic disorder of the pilosebaceous apparatus associated with an increase in sebum secretion. It is characterized by open comedones (blackheads), closed comedones (whiteheads), and pustular nodules. The cause is unknown, but heredity and age are predisposing factors.		02.9410
Staphylococcal Skin Infections
Infections to the skin caused by bacteria of the genus STAPHYLOCOCCUS.		02.9410